These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18020718)

  • 1. Modeling population heterogeneity in appearance- and performance-enhancing drug (APED) use: applications of mixture modeling in 400 regular APED users.
    Hildebrandt T; Langenbucher JW; Carr SJ; Sanjuan P
    J Abnorm Psychol; 2007 Nov; 116(4):717-33. PubMed ID: 18020718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fitness supplements as a gateway substance for anabolic-androgenic steroid use.
    Hildebrandt T; Harty S; Langenbucher JW
    Psychol Addict Behav; 2012 Dec; 26(4):955-62. PubMed ID: 22486333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body image disturbance in 1000 male appearance and performance enhancing drug users.
    Hildebrandt T; Alfano L; Langenbucher JW
    J Psychiatr Res; 2010 Oct; 44(13):841-6. PubMed ID: 20110092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting future anabolic-androgenic steroid use intentions with current substance use: findings from an internet-based survey.
    Dunn M; Mazanov J; Sitharthan G
    Clin J Sport Med; 2009 May; 19(3):222-7. PubMed ID: 19423975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting intentions for long-term anabolic-androgenic steroid use among men: a covariance structure model.
    Hildebrandt T; Langenbucher J; Carr S; Sanjuan P; Park S
    Psychol Addict Behav; 2006 Sep; 20(3):234-40. PubMed ID: 16938061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Appearance- and Performance-Enhancing Drugs on Personality Traits.
    Zaami S; Minutillo A; Sirignano A; Marinelli E
    Front Psychiatry; 2021; 12():730167. PubMed ID: 34630182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic dilemma of pathological appearance and performance enhancing drug use.
    Hildebrandt T; Lai JK; Langenbucher JW; Schneider M; Yehuda R; Pfaff DW
    Drug Alcohol Depend; 2011 Mar; 114(1):1-11. PubMed ID: 21115306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.
    Larance B; Degenhardt L; Copeland J; Dillon P
    Drug Alcohol Rev; 2008 Nov; 27(6):679-86. PubMed ID: 18825549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosocial correlates of gap time to anabolic-androgenic steroid use.
    Klimek P; Hildebrandt T
    Int J Eat Disord; 2018 Jun; 51(6):535-541. PubMed ID: 29542171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids.
    Petersson A; Garle M; Holmgren P; Druid H; Krantz P; Thiblin I
    Drug Alcohol Depend; 2006 Feb; 81(3):241-9. PubMed ID: 16137840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anabolic steroid use in high school students.
    Pallesen S; Jøsendal O; Johnsen BH; Larsen S; Molde H
    Subst Use Misuse; 2006; 41(13):1705-17. PubMed ID: 17118811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of the appearance and performance enhancing drug use schedule.
    Hildebrandt T; Langenbucher JW; Lai JK; Loeb KL; Hollander E
    Addict Behav; 2011 Oct; 36(10):949-58. PubMed ID: 21640487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anabolic androgenic steroids: a survey of 500 users.
    Parkinson AB; Evans NA
    Med Sci Sports Exerc; 2006 Apr; 38(4):644-51. PubMed ID: 16679978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multisubstance use as a feature of addiction to anabolic-androgenic steroids.
    Skarberg K; Nyberg F; Engstrom I
    Eur Addict Res; 2009; 15(2):99-106. PubMed ID: 19182484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A typology of cannabis-related problems among individuals with repeated illegal drug use in the first three decades of life: Evidence for heterogeneity and different treatment needs.
    Wittchen HU; Behrendt S; Höfler M; Perkonigg A; Rehm J; Lieb R; Beesdo K
    Drug Alcohol Depend; 2009 Jun; 102(1-3):151-7. PubMed ID: 19362792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent class analysis of substance abuse patterns.
    Uebersax JS
    NIDA Res Monogr; 1994; 142():64-80. PubMed ID: 9243533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of steroids for self-enhancement: an epidemiologic/societal perspective.
    Yesalis CE
    AIDS Read; 2001 Mar; 11(3):157-60. PubMed ID: 17004353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anabolic-androgenic steroids: use and abuse in pediatric patients.
    Kerr JM; Congeni JA
    Pediatr Clin North Am; 2007 Aug; 54(4):771-85, xii. PubMed ID: 17723876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of 100 anabolic-androgenic steroid users.
    Copeland J; Peters R; Dillon P
    Med J Aust; 1998 Mar; 168(6):311-2. PubMed ID: 9549549
    [No Abstract]   [Full Text] [Related]  

  • 20. Subtypes of depression in a nationally representative sample.
    Carragher N; Adamson G; Bunting B; McCann S
    J Affect Disord; 2009 Feb; 113(1-2):88-99. PubMed ID: 18644628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.